Use ENTRESTO™ in place of ACEis and ARBs for HFrEF patients1
ENTRESTO was studied in the largest HF trial ever conducted2
• Trial stopped early due to finding of significantly reduced risk of CV death and
the primary end point being met3
ENTRESTO has been proven superior to enalapril, a current
standard-of-care4 medication1
• Superiority vs enalapril, a standard-of-care ACEi therapy, across a range
of NYHA class II–IV patients with chronic HF and reduced ejection fraction
REDUCED RISK OF
CV DEATH OR FIRST
HF HOSPITALIZATION
VS T